Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe(−/−) mice

Atherosclerosis (AS) is the leading cause of heart attacks, stroke, and peripheral vascular disease. Berberine (BBR), a botanical medicine, has diversified anti-atherosclerotic effects but with poor absorption. The aim of this study was to develop an effective BBR-entrapped nano-system for treating...

Full description

Bibliographic Details
Main Authors: Xiaolei Ma, Tingting Zhang, Zhigang Luo, Xiaolin Li, Miao Lin, Rui Li, Peng Du, Xiaoyou Yu, Chen Ma, Pengju Yan, Jin Su, Lulu Wang, Yuhuan Li, Jiandong Jiang
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383520305402
id doaj-e30e8d80973740218c656a37394cc269
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Xiaolei Ma
Tingting Zhang
Zhigang Luo
Xiaolin Li
Miao Lin
Rui Li
Peng Du
Xiaoyou Yu
Chen Ma
Pengju Yan
Jin Su
Lulu Wang
Yuhuan Li
Jiandong Jiang
spellingShingle Xiaolei Ma
Tingting Zhang
Zhigang Luo
Xiaolin Li
Miao Lin
Rui Li
Peng Du
Xiaoyou Yu
Chen Ma
Pengju Yan
Jin Su
Lulu Wang
Yuhuan Li
Jiandong Jiang
Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe(−/−) mice
Acta Pharmaceutica Sinica B
Atherosclerosis
Berberine
Functional nano-vector
Endothelial activation
author_facet Xiaolei Ma
Tingting Zhang
Zhigang Luo
Xiaolin Li
Miao Lin
Rui Li
Peng Du
Xiaoyou Yu
Chen Ma
Pengju Yan
Jin Su
Lulu Wang
Yuhuan Li
Jiandong Jiang
author_sort Xiaolei Ma
title Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe(−/−) mice
title_short Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe(−/−) mice
title_full Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe(−/−) mice
title_fullStr Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe(−/−) mice
title_full_unstemmed Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe(−/−) mice
title_sort functional nano-vector boost anti-atherosclerosis efficacy of berberine in apoe(−/−) mice
publisher Elsevier
series Acta Pharmaceutica Sinica B
issn 2211-3835
publishDate 2020-09-01
description Atherosclerosis (AS) is the leading cause of heart attacks, stroke, and peripheral vascular disease. Berberine (BBR), a botanical medicine, has diversified anti-atherosclerotic effects but with poor absorption. The aim of this study was to develop an effective BBR-entrapped nano-system for treating AS in high-fat diet (HFD)-fed Apoe(−/−) mice, and also explore the possible underlying mechanisms involved. Three d-α-tocopherol polyethylene glycol (PEG) succinate (TPGS) analogues with different PEG chain lengths were synthesized to formulate BBR-entrapped micelles. HFD-fed Apoe(−/−) mice were administered with optimized formula (BBR, 100 mg/kg/day) orally for 5 months. The artery plaque onset and related metabolic disorders were evaluated, and the underlying mechanisms were studied. Our data showed that, BT1500M increased BBR deposition in liver and adipose by 107.6% and 172.3%, respectively. In the Apoe(−/−) mice, BT1500M ameliorated HFD-induced hyperlipidemia and lipid accumulation in liver and adipose. BT1500M also suppressed HFD-induced chronic inflammation as evidenced by the reduced liver and adipose levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β); and decreased plasma level of TNF-α, IL-6, IL-1β, interferon-γ (IFN-γ), monocyte chemotactic protein (MCP), and macrophage inflammatory factor (MIP). The mechanism study showed that BT1500M changed Ampk and Nf-κb gene expression, and interrupted a crosstalk process between adipocytes and macrophages. Further investigation proved that BT1500M decreased endothelial lesion and subsequent macrophage activation, cytokines release, as well as cholesteryl ester gathering in the aortic arch, resulting in ameliorated artery plaque build-up. Our results provide a practical strategy for treating AS using a BBR-entrapped nano-system.
topic Atherosclerosis
Berberine
Functional nano-vector
Endothelial activation
url http://www.sciencedirect.com/science/article/pii/S2211383520305402
work_keys_str_mv AT xiaoleima functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT tingtingzhang functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT zhigangluo functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT xiaolinli functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT miaolin functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT ruili functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT pengdu functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT xiaoyouyu functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT chenma functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT pengjuyan functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT jinsu functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT luluwang functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT yuhuanli functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
AT jiandongjiang functionalnanovectorboostantiatherosclerosisefficacyofberberineinapoemice
_version_ 1724513935970795520
spelling doaj-e30e8d80973740218c656a37394cc2692020-11-25T03:44:35ZengElsevierActa Pharmaceutica Sinica B2211-38352020-09-0110917691783Functional nano-vector boost anti-atherosclerosis efficacy of berberine in Apoe(−/−) miceXiaolei Ma0Tingting Zhang1Zhigang Luo2Xiaolin Li3Miao Lin4Rui Li5Peng Du6Xiaoyou Yu7Chen Ma8Pengju Yan9Jin Su10Lulu Wang11Yuhuan Li12Jiandong Jiang13State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaDepartment of Pharmacy, Jiamusi University, Jiamusi 154007, ChinaDepartment of Pharmacy, Jiamusi University, Jiamusi 154007, ChinaState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Corresponding authors. Tel./fax: +86 10 63017757.Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Corresponding authors. Tel./fax: +86 10 63017757.State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaAtherosclerosis (AS) is the leading cause of heart attacks, stroke, and peripheral vascular disease. Berberine (BBR), a botanical medicine, has diversified anti-atherosclerotic effects but with poor absorption. The aim of this study was to develop an effective BBR-entrapped nano-system for treating AS in high-fat diet (HFD)-fed Apoe(−/−) mice, and also explore the possible underlying mechanisms involved. Three d-α-tocopherol polyethylene glycol (PEG) succinate (TPGS) analogues with different PEG chain lengths were synthesized to formulate BBR-entrapped micelles. HFD-fed Apoe(−/−) mice were administered with optimized formula (BBR, 100 mg/kg/day) orally for 5 months. The artery plaque onset and related metabolic disorders were evaluated, and the underlying mechanisms were studied. Our data showed that, BT1500M increased BBR deposition in liver and adipose by 107.6% and 172.3%, respectively. In the Apoe(−/−) mice, BT1500M ameliorated HFD-induced hyperlipidemia and lipid accumulation in liver and adipose. BT1500M also suppressed HFD-induced chronic inflammation as evidenced by the reduced liver and adipose levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β); and decreased plasma level of TNF-α, IL-6, IL-1β, interferon-γ (IFN-γ), monocyte chemotactic protein (MCP), and macrophage inflammatory factor (MIP). The mechanism study showed that BT1500M changed Ampk and Nf-κb gene expression, and interrupted a crosstalk process between adipocytes and macrophages. Further investigation proved that BT1500M decreased endothelial lesion and subsequent macrophage activation, cytokines release, as well as cholesteryl ester gathering in the aortic arch, resulting in ameliorated artery plaque build-up. Our results provide a practical strategy for treating AS using a BBR-entrapped nano-system.http://www.sciencedirect.com/science/article/pii/S2211383520305402AtherosclerosisBerberineFunctional nano-vectorEndothelial activation